SEC Form 4 · accession 0001179110-17-013103
Editas Medicine, Inc. · EDIT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Katrine Bosley
Officer — President and CEO · Director
Period of report
Oct 2, 2017
Accepted (ET)
Oct 4, 2017 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001650664
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Oct 2, 2017 | S | 8,133 | $24.7706 | D | 1,399,630 | D | |
| Common StockF3 | Oct 2, 2017 | S | 200 | $25.33 | D | 1,399,430 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017.
- F2This transaction was executed in multiple trades at prices ranging from $24.2 to $25.17. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected
- F3This transaction was executed in multiple trades at prices ranging from $25.32 to $25.34. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected